Patent lodged for anti-ageing skin process
Earlier today, our long term Wise-Owl cannabis Investment, Bod Australia (ASX:BOD) announced that it had lodged an international patent application for a novel delivery device to combat the skin ageing process.
This represents another innovative product BOD is developing that addresses a substantial market. According to Precedence Research, the global anti-aging market size is expected to grow at a compound annual growth rate of 7.9% from 2022 through to 2030, hitting ~US$119.6 billion in 2030.
The delivery device comprises a novel family of proteins discovered through a research collaboration with the University of Technology Sydney (UTS).
Recent testing results showed that treatment of human skin cells with Bod’s delivery device reduces cell death to UV light exposure by up to 30% when compared to untreated cells, as well as protection against harsh skin oxidants such as hydrogen peroxide.
BOD is now actively advancing licensing opportunities for this opportunity.
We’re thinking skin care products (many of which have dubious or no clinical evidence behind their claims) could benefit from BOD’s patented, clinically proven tech. Sunscreen comes to mind as well - basically any topical skin product.
Today’s news follows BOD’s announcement last month of the transformative acquisition of the Aqua Phase technology - a cannabis product and process technology that allows more rapid onset, better efficacy and lower dosage rates of cannabidiol (CBD) products, resulting in raw material cost savings and fewer patient side effects.
BOD is certainly doubling down on its R&D with a very active clinical trial pipeline - the novel delivery device to combat the skin ageing process being one of 11 projects progressing.
We like that BOD is progressing multiple innovations and products addressing sizable markets. We are keen to see how Aqua Phase can be incorporated into the current clinical trials into an over-the-counter insomnia treatment, as well as the trials addressing long Covid. Our latest commentary on the recent acquisition including our Big Bet for BOD can be found here - BOD's Big Bet, will it pay off?
